Exhibit 99.1 ODDITY TECH REPORTS RECORD FIRST QUARTER RESULTS, RAISES FULL YEAR OUTLOOK NEW YORK, April 29, 2025 -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2025. "Our Q125 results exceeded our expectations across all metrics and allow us to raise our full year outlook. We delivered an outstanding result for our biggest quarter of the year, setting us up to overdeliver on our financial algorithm in 2025," said Oran Holtzman, ODDITY co-founder ...

Core Insights - ODDITY Tech Ltd. reported strong financial results for Q1 2025, exceeding expectations across all metrics and raising its full-year outlook [2][3][9] - The beauty industry is undergoing significant transformation, with a shift towards online shopping and high-performance products, which ODDITY is well-positioned to capitalize on [2][5] Financial Performance - Q1 2025 net revenue reached $268 million, a 27% increase year-over-year from $212 million in Q1 2024 [4][6] - Gross profit for Q1 2025 was $201 million, up 29% from $156 million in the same quarter last year, with a gross margin of 74.9% [4][6] - Adjusted EBITDA for Q1 2025 was $52 million, representing a 9% increase from $48 million in Q1 2024 [6][31] - Net income for Q1 2025 was $38 million, compared to $33 million in Q1 2024, with an adjusted net income of $42 million [4][6] Operational Highlights - ODDITY achieved double-digit revenue growth for its brands IL MAKIAGE and SpoiledChild [5] - The company is accelerating its international expansion and progressing towards the launch of Brand 3 in Q3 and Q4 of 2025 [5][9] - ODDITY generated $87 million in free cash flow and maintained a strong balance sheet with $257 million in cash and no outstanding debt as of March 31, 2025 [5][7] Financial Outlook - ODDITY raised its 2025 financial outlook, now expecting net revenue between $790 million and $798 million, reflecting a year-over-year growth of 22% to 23% [9][11] - The company anticipates a gross margin of approximately 71% and adjusted EBITDA between $157 million and $161 million for the full year [11][12] - For Q2 2025, ODDITY projects net revenue between $235 million and $239 million, with a gross margin of 70.5% [12]

Oddity ( ODD ) is not your average beauty retailer. It is a digital native beauty player that bypasses classical retailers and sells directly to consumers with outstanding profitability and efficiency. The key to the businessEx-hedge fund analyst with a strong interest in finding winners and losers in industries where corporate strategy matters most. I focus on analysing the market structure, competitive positioning and strategic catalysts that lead to money-making ideas in varying time horizons. Enjoy read ...

Company Overview - ODDITY Tech Ltd. is a consumer tech company focused on building and scaling digital-first brands to disrupt the offline-dominated beauty and wellness industries [3] - The company serves approximately 60 million users through its AI-driven online platform, utilizing data science to identify consumer needs and develop beauty and wellness products [3] - ODDITY owns brands such as IL MAKIAGE and SpoiledChild, with headquarters in New York City, an R&D center in Tel Aviv, Israel, and a biotechnology lab in Boston [3] Upcoming Financial Results - ODDITY will release its first quarter 2025 financial results after the market close on April 29, 2025 [1] - A conference call to discuss the results will take place on April 30, 2025, at 8:30 a.m. Eastern Time [1] - Participants can access the call via specific dial-in numbers and a webcast available on the company's investor website [2]

Technical Analysis - Oddity Tech (ODD) has surpassed resistance at the 50-day moving average, indicating a potential short-term bullish trend [1] - The 50-day simple moving average is a key indicator for traders and analysts to determine support or resistance levels [1] Performance Metrics - ODD has experienced a rally of 5.1% over the past four weeks, suggesting positive momentum [2] - The company currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [2] Earnings Estimates - There have been three upward revisions in earnings estimates for the current fiscal year, with no downward revisions in the past two months [2] - The consensus estimate for ODD has also increased, reinforcing the bullish outlook [2][3] Investment Consideration - Given the positive technical factors and earnings estimate revisions, ODD may present a potential investment opportunity for further gains in the near future [3]

Group 1 - Oddity Tech (ODD) has reached a significant support level and shows potential for investors from a technical perspective, having recently broken through the 20-day moving average, indicating a short-term bullish trend [1] - The 20-day simple moving average is a widely used trading tool that helps smooth out price fluctuations and provides more trend reversal signals than longer-term moving averages, with a price above this average indicating a positive trend [2] - ODD shares have increased by 12.4% over the past four weeks, and the company holds a Zacks Rank 3 (Hold), suggesting potential for continued gains [3] Group 2 - Positive earnings estimate revisions further strengthen the bullish outlook for ODD, with no earnings estimates lowered in the past two months and three raised estimates for the current fiscal year, leading to an increase in the consensus estimate [3] - The combination of favorable earnings estimate revisions and the stock hitting a key technical level suggests that investors should monitor ODD for potential gains in the near future [4]

VALBY, Denmark, March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA).H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.The ODD in Japan adds to other important designations: the SAKIGAKE designation by Japan's MHLW in March 2023, the Orphan Drug ...

Oddity Tech (ODD -0.53%) reported its fourth-quarter and full-year 2024 earnings on February 26, 2025, highlighting strong growth and investments in future expansion. The company is seeing growth through repeat sales and its direct-to-consumer business, with new brands on the horizon in 2025 and 2026.Direct-to-Consumer Model Drives Superior PerformanceThe company's digital approach is delivering strong results amid broader industry headwinds. Oddity's direct connection with consumers enables precise invento ...

Financial Data and Key Metrics Changes - In 2024, the company achieved a revenue growth of 27% to $647 million and delivered adjusted EBITDA of $150 million at a margin of 23.3%, representing a 40% year-over-year increase in adjusted EBITDA [7][8] - The company generated $134 million of free cash flow, converting over 130% of net income into cash, and maintained strong momentum with revenue growth of 27% in Q4 [8][56] - The gross margin expanded to 72.7%, up 330 basis points year-over-year, exceeding guidance of 68% [53] Business Line Data and Key Metrics Changes - Both brands, Il Makiage and Spoiled Child, experienced double-digit revenue growth in 2024, with Il Makiage surpassing $500 million in revenue and Spoiled Child reaching $150 million [9][10] - The repeat sales metric increased significantly, with repeat revenue accounting for over 60% of total business revenue in 2024, up from less than 50% in previous years [12][82] Market Data and Key Metrics Changes - The company noted a shift towards online sales, which is expected to continue growing, with the belief that online penetration could double from current levels [14][77] - The company is strategically expanding its international presence, particularly in markets like the UK, Germany, and Australia, with positive early indications [25][26] Company Strategy and Development Direction - The company is focused on investing in growth areas such as Oddity Labs, new brands, and AI technologies to drive future growth [7][24] - The launch of brand three, a telehealth platform, is set for the second half of 2025, targeting medical-grade skin and body issues [28][100] - The company aims to leverage its direct-to-consumer model to maintain a competitive edge, avoiding excess inventory issues faced by wholesale brands [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to perform well despite macroeconomic challenges, citing strong repeat sales and a resilient business model [72][140] - The outlook for 2025 includes a commitment to achieving 20% revenue growth and a 20% adjusted EBITDA margin, despite planned investments in growth initiatives [59][60] Other Important Information - The company repurchased 3.6 million shares for approximately $147 million during 2024, with $103 million remaining on its buyback authorization [57][58] - The company exited 2024 with $169 million in cash equivalents and investments, maintaining a zero-debt position [58] Q&A Session Summary Question: Can you elaborate on your international strategy and why now? - Management indicated that the decision to accelerate international growth is strategic, focusing on smaller markets to spread growth effectively [71] Question: Are you seeing any weakness in consumer spending due to macro concerns? - Management noted that the shift to online sales is a significant factor, and they are not experiencing the same promotional pressures as competitors [75] Question: Can you provide insights on repeat purchases and growth from Il Makiage? - Management reported that repeat purchases account for over 60% of revenue, with a twelve-month net revenue repeat rate exceeding 100% [82] Question: What are the key milestones for brand three? - Management highlighted that brand three is set to launch with a focus on skin and body issues, with significant investments made to ensure a successful rollout [96][100] Question: How do you balance organic growth versus M&A for Oddity Labs? - Management stated that they are open to M&A opportunities to enhance capabilities, particularly in pharma, while also expanding their internal team [123]

Core Insights - Oddity Tech reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and showing an increase from $0.17 per share a year ago, resulting in an earnings surprise of 53.85% [1] - The company achieved revenues of $123.64 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 3.17% and increasing from $97.25 million year-over-year [2] - Oddity Tech has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of Oddity Tech's stock will largely depend on management's commentary during the earnings call and the sustainability of the recent price movements [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.53 on revenues of $255.24 million, and for the current fiscal year, it is $1.74 on revenues of $772.64 million [7] Industry Context - The Internet - Software industry, to which Oddity Tech belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Oddity Tech's stock performance [5][6]